Key Takeaways Shares of KalVista Pharmaceuticals (KALV) have soared 36% in the past week, all thanks to the FDA's approval of its lead pipeline drug for the hereditary angioedema (HAE) indication. Earlier this week, the FDA approved the company's novel plasma kallikrein inhibitor, sebetralstat, for the treatment of acute (sudden) HAE attacks in individuals aged 12 years and older. The drug will be marketed under the brand name Ekterly. This latest approval makes Ekterly the first and only oral on-demand the ...

Core Insights - KalVista Pharmaceuticals, Inc. received FDA approval for its oral on-demand Hereditary Angioedema plasma kallikrein inhibitor drug EKTERLY (sebetralstat) on July 7, 2025, marking a significant milestone for the company [2]. Company Overview - KalVista Pharmaceuticals is focused on developing treatments for hereditary angioedema, a rare genetic condition that causes severe swelling [2]. Market Context - The approval of EKTERLY positions KalVista favorably within the biotech sector, particularly in the niche market of hereditary angioedema treatments, which may enhance its competitive edge [2].